Sell Steven

CEO Steven buys 42,426 shares of AGL; third open-market purchase, prior two at same ticker posted +2296.3% and +2730.5% 30-day returns.

Steven, CEO & President, purchased 42,426 shares of Agilon Health on 2025-03-14, increasing his holdings to 355,310 shares (+13.6% net change). His prior two open-market purchases at AGL (2024-09-12 and 2023-11-21) each delivered substantial 30-day returns of +2296.3% and +2730.5% respectively, establishing a pattern of exceptionally well-timed accumulation at this ticker. The current stock price of $108.00 represents a -42.6% decline from the 52-week high of $188.00, though the stock has rallied +26.3% over the past 30 days and +121.5% over 90 days. A cluster of 2 other insiders also purchased shares within the past 14 days, indicating coordinated insider accumulation. However, context matters: the company remains unprofitable (net income $-117,615,000.00 for the latest quarter) despite strong topline momentum (annual revenue growth of +40.4%), and the current purchase price is not disclosed in the filing.

CEO Steven bought 20,000 AGL shares at $3.36 (Sept 2024); stock now $82.00, -83.4% from 52-week high of $495.00.

Steven, CEO & President, purchased 20,000 shares at $3.36 on 2024-09-12, increasing his holdings by 42.0% to 67,590 shares post-transaction. The stock has deteriorated sharply since the purchase: it now trades at $82.00, representing a -83.4% decline from the 52-week high of $495.00, and a -32.4% drop over the past 30 days and -51.3% over 90 days. His prior purchase at this ticker on 2023-11-21 generated +2730.5% return over 30 days and +1496.0% over 90 days, demonstrating successful timing on that trade. However, the current transaction occurred after a severe drawdown and substantial time has passed since that prior success, so historical accuracy does not automatically predict outcomes in a deteriorating price environment. Notably, the company remains unprofitable (net income $-30.7M most recent quarter) despite strong revenue growth of +59.4% annually, which may contextually inform the stock's weakness.